Journal article
Omalizumab for asthma in adults and children
Abstract
BACKGROUND: Asthma is a respiratory (airway) condition that affects an estimated 300 million people worldwide and is associated with significant morbidity and mortality. Omalizumab is a monoclonal antibody that binds and inhibits free serum immunoglobulin E (IgE). It is called an 'anti-IgE' drug. IgE is an immune mediator involved in clinical manifestations of asthma. A recent update of National Institute for Health and Care Excellence (NICE) …
Authors
Normansell R; Walker S; Milan SJ; Walters EH; Nair P
Journal
Cochrane Database of Systematic Reviews, Vol. 2014, No. 1,
Publisher
Wiley
DOI
10.1002/14651858.cd003559.pub4
ISSN
1361-6137